[Skip to Content]
[Skip to Content Landing]
From The Medical Letter on Drugs and Therapeutics
February 27, 2018

A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B)

JAMA. 2018;319(8):822-823. doi:10.1001/jama.2018.1097

The FDA has approved a two-dose hepatitis B virus (HBV) vaccine (Heplisav-B—Dynavax) for use in adults ≥18 years old. The three other HBV vaccines marketed in the US are usually administered in 3 doses. Engerix-B and Recombivax HB are licensed for use in persons of all ages. A combination hepatitis A/B vaccine (Twinrix) contains the same hepatitis B component as Engerix-B and is licensed for use only in adults.1